ClinicalTrials.gg
CompletedNCT00091715Updated Aug 30, 2011

Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

A Phase 3 interventional study of bosentan and placebo in Pulmonary Hypertension, sponsored by Actelion. Completed at 34 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-08-30.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
2nd of 18
185 · median 37
Started
2004
with 1 other
Phase 3
7 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is one of 2 that started in 2004, is one of 7 in phase 3, and was the 1st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.

03

Conditions studied

  • Pulmonary Hypertension

Browse trials for

Keywords

  • Pulmonary arterial hypertension
  • PAH
  • PPH
  • bosentan
  • early
04

In context

Pulmonary Arterial Hypertension Reclassified

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's enrollment of 185 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PAH Class II
  • Significant elevation of mean pulmonary arterial pressure
  • Significant elevation of pulmonary vascular resistance at rest
  • Limited 6-minute walk distance

Exclusion criteria

Exclusion Criteria:

  • PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt
  • Restrictive or obstructive lung disease
  • Significant vasoreactivity
  • Treatments for PAH (within 4 weeks of randomization)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    1

    62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.

    Drug: bosentan

  • Placebo comparator
    2

    placebo for 6 months followed by an open label period

    Drug: placebo

Interventions

  • 65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study

    Also known as: Tracleer

  • Drugplacebo

    placebo for 6 months followed by an open-label period

07

What researchers measure

Primary outcomes

  1. exercise capacity

    Time frame: Baseline to end of study

  2. cardiac hemodynamics

    Time frame: Baseline to end of study

08

Study locations

34 sites
  • University of Alabama-Birmingham
    Birmingham, Alabama 35294, United States
  • Harbor UCLA Medical Center
    Torrance, California 90509, United States
  • Tufts- New England Medical Center
    Boston, Massachusetts 02111, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • St. Paul University Hospital
    Dallas, Texas 75390, United States
  • The Prince Charles Hospital
    Brisbane, 4032, Australia
  • Royal Prince Albert Hospital
    Camperdown, Australia
  • St. Vincent's Hospital
    Darlinghurst, Australia
  • General Hospital of Vienna
    Vienna, 1180, Austria
  • UZ Gasthuisberg
    Leuven, Belgium
  • University of Calgary
    Calgary, Alberta T1Y 6J4, Canada
  • University of Alberta
    Edmonton, Alberta T6G 2B7, Canada
  • Halifax Infirmary
    Halifax, Nova Scotia B3H 3A7, Canada
  • Victoria Medical Centre
    Hamilton, Ontario L8L 5G4, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Centre de Pneumologie de L'Hospital Laval
    Sainte Foy, Quebec G1V 4G5, Canada
  • Queen Mary Hospital
    Hong Kong, China
  • Interni klinika VFN
    Prague, Czech Republic
  • Marseille-Timone
    Marseille, 13005, France
  • Universitat Greifswald
    Greifswald, 17487, Germany
  • Universitat Greifswald
    Greifswald, Germany
  • Universitarsklinikum Hamburg-Eppendorf
    Hamburg, Germany
  • Medizinische Universitatsklinik
    Heidelberg, Germany
  • Universitatsklinikim Leipzig
    Leipzig, Germany
  • Klinikum der Universitat Regensburg
    Regensburg, Germany
  • Policlinico S. Orsola-Malpighi
    Bologna, Italy
  • VU Medisch Centrum
    Amsterdam, Netherlands
  • University Hospital Maastricht
    Maastricht, Netherlands
  • Hospital Clinic
    Barcelona, Spain
  • Hospital Valle d'Hebron
    Barcelona, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Zurich University Hospital
    Zurich, Switzerland
  • Papworth Hospital
    Cambridge, CB3 8RE, United Kingdom
09

References and documents

Publications

  • Galie N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008 Jun 21;371(9630):2093-100. doi: 10.1016/S0140-6736(08)60919-8. PubMed 18572079 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Nov 2006 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2004
First posted
Sep 20, 2004
Start
Apr 2004
Primary completionActual
Nov 2006
CompletionActual
Feb 2011
Last update
Aug 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00091715
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Sep 20, 2004
Start date
Apr 2004
Primary completion
Nov 2006
Completion
Feb 2011
Last update
Aug 30, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion